Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland.

Elżbieta Złowocka-PerłowskaAleksandra Tołoczko-GrabarekSteven A NarodJan Lubiński

Published in: Hereditary cancer in clinical practice (2022)

In conclusion, we found no difference in the prevalence of BRCA1 and BRCA2 founder mutations between cases and healthy controls. The mutations BRCA1 and BRCA2 seem not to play a role in bladder and kidney cancer development in Polish patients.

Keyphrases

breast cancer risk
papillary thyroid
spinal cord injury
end stage renal disease
newly diagnosed
ejection fraction
squamous cell
squamous cell carcinoma
prognostic factors
dna repair
dna damage
patient reported outcomes
oxidative stress
childhood cancer
urinary tract